Rocket One (RKTO) Restructuring Costs (2023 - 2024)
Rocket One's (RKTO) quarterly Restructuring Costs came in at $326880.0 in Q1 2024, down 41.61% quarter-over-quarter from $559848.0 in Q4 2023.
Analysis
Rocket One (RKTO) Restructuring Costs (2023 - 2024) Analysis & Trends
Rocket One has disclosed Restructuring Costs across 2 years of filings, most recently posting $326880.0 for Q1 2024.
- In Q1 2024, Restructuring Costs changed N/A year-over-year to $326880.0; the TTM figure through Mar 2024 stood at $1.0 million (changed N/A YoY), while the FY2023 annual figure was $1.0 million, changed N/A from the prior year.
- Restructuring Costs came in at $326880.0 for Q1 2024 at Rocket One, down from $559848.0 in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $559848.0 in Q4 2023 to a low of $46171.0 in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 212.04 Bn | 198.05 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.35 Bn | 178.17 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.22 Bn | 124.37 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.94 Bn | 74.94 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.53 Bn | 56.34 Bn | 1.37 Bn |
| 6 | Moderna | 54.25 Bn | 49.11 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.41 Bn | 31.10 Bn | 992.69 Mn |
| 8 | Biogen | 31.19 Bn | 29.91 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn |
| 10 | Rocket One | 13.87 Mn | 5.98 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | 326,880.00 |
| Dec 31, 2023 | 559,848.00 |
| Sep 30, 2023 | 67,101.00 |
| Jun 30, 2023 | 46,171.00 |